Literature DB >> 34704159

Sexual Function After Voluntary Castration.

Erik Wibowo1, Samantha T S Wong2, Richard J Wassersug3, Thomas W Johnson4.   

Abstract

Some genetic males undergo voluntary castration, with and without hormonal supplementation. Here, we investigate the sexual function of 163 such individuals (average age = 52 ± 16-years-old). Specifically, we explored how hormonal, social, and psychological factors play a role in their sexual function. In this study, 47% identified their gender as "eunuch", and 36% identified their gender as "man." Furthermore, 64% were in a relationship (80% with a woman), and 28% had a strong attraction for both sexes (Kinsey 2-4). We found that castrated individuals with androgen supplementation have higher sexual function than those without any hormone supplementation. Individuals with anxiety symptoms reported better sexual parameters (better orgasm satisfaction, easier to achieve an erection and an orgasm) than those without anxiety symptoms. Among those low in anxiety, individuals without hormone supplementation had a weaker sex drive and more difficulty in getting sexually aroused than those on supplemental estrogen or androgen. Hierarchical multiple regressions indicated that control variables (i.e., age, depressive symptoms, time since castration, type of hormone supplementation) accounted for 13-30% of the variances in sexual parameters. Including sexual guilt in the models predicted 4-8% additional variances in all sexual parameters except for ease in getting and maintaining an erection. Adding in participants' sexual trauma scores accounted for an additional 3.7% in the strength of their reported sex drive. In conclusion, various factors-hormone therapy, anxiety, sexual guilt, and childhood trauma-may influence the sexual outcomes for castrated individuals.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Androgen deprivation; Castration; Estrogen; Eunuchs; Psychosexual; Sexual function

Mesh:

Year:  2021        PMID: 34704159     DOI: 10.1007/s10508-021-02094-6

Source DB:  PubMed          Journal:  Arch Sex Behav        ISSN: 0004-0002


  19 in total

1.  Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer.

Authors:  Kathryn T Dinh; David D Yang; Kevin T Nead; Gally Reznor; Quoc-Dien Trinh; Paul L Nguyen
Journal:  Int J Urol       Date:  2017-07-22       Impact factor: 3.369

2.  The Revised Mosher Sex-Guilt Scale: its psychometric properties and a proposed ten-item version.

Authors:  Louis H Janda; Sharnail D Bazemore
Journal:  J Sex Res       Date:  2011-07

3.  A meta-analysis of disparities in childhood sexual abuse, parental physical abuse, and peer victimization among sexual minority and sexual nonminority individuals.

Authors:  Mark S Friedman; Michael P Marshal; Thomas E Guadamuz; Chongyi Wei; Carolyn F Wong; Elizabeth Saewyc; Ron Stall
Journal:  Am J Public Health       Date:  2011-06-16       Impact factor: 9.308

Review 4.  Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.

Authors:  Giovanni Corona; Giulia Rastrelli; Abraham Morgentaler; Alessandra Sforza; Edoardo Mannucci; Mario Maggi
Journal:  Eur Urol       Date:  2017-04-20       Impact factor: 20.096

5.  Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.

Authors:  Duncan C Gilbert; Trinh Duong; Howard G Kynaston; Abdulla A Alhasso; Fay H Cafferty; Stuart D Rosen; Subramanian Kanaga-Sundaram; Sanjay Dixit; Marc Laniado; Sanjeev Madaan; Gerald Collins; Alvan Pope; Andrew Welland; Matthew Nankivell; Richard Wassersug; Mahesh K B Parmar; Ruth E Langley; Paul D Abel
Journal:  BJU Int       Date:  2016-11-12       Impact factor: 5.588

6.  Sexual function in prostatic cancer patients treated with radiotherapy, orchiectomy or oestrogens.

Authors:  B Bergman; J E Damber; B Littbrand; K Sjögren; R Tomić
Journal:  Br J Urol       Date:  1984-02

Review 7.  Sexual abuse of boys: definition, prevalence, correlates, sequelae, and management.

Authors:  W C Holmes; G B Slap
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

8.  Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer.

Authors:  Kathryn T Dinh; Gally Reznor; Vinayak Muralidhar; Brandon A Mahal; Michelle D Nezolosky; Toni K Choueiri; Karen E Hoffman; Jim C Hu; Christopher J Sweeney; Quoc-Dien Trinh; Paul L Nguyen
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 50.717

9.  Gender Preference in the Sexual Attractions, Fantasies, and Relationships of Voluntarily Castrated Men.

Authors:  Ariel B Handy; Robyn A Jackowich; Erik Wibowo; Thomas Wayne Johnson; Richard J Wassersug
Journal:  Sex Med       Date:  2016-03       Impact factor: 2.491

10.  Robust evidence for bisexual orientation among men.

Authors:  Jeremy Jabbour; Luke Holmes; David Sylva; Kevin J Hsu; Theodore L Semon; A M Rosenthal; Adam Safron; Erlend Slettevold; Tuesday M Watts-Overall; Ritch C Savin-Williams; John Sylla; Gerulf Rieger; J Michael Bailey
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-20       Impact factor: 11.205

View more
  1 in total

1.  Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.

Authors:  E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus
Journal:  Int J Transgend Health       Date:  2022-09-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.